MAGE-A3 Antigen-Specific Cancer Immunotherapy (ASCI)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MAGE-A3 Antigen-Specific Cancer Immunotherapy (ASCI), covering 2016-04-04 to 2016-04-04. Get the full timeline:
Most recent: Clinical Trial Update: Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI [EARLY_Phase 1]